Online citations, reference lists, and bibliographies.
← Back to Search

Preparation Of Polymeric Nanoparticles Of Cyclosporin A Using Infrared Pulsed Laser.

G. Takebe, T. Takagi, M. Suzuki, M. Hiramatsu
Published 2011 · Materials Science, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Nanoparticle formation of poorly water-soluble drugs is a means of providing much benefit for improving solubility and bioavailability. We showed that laser irradiation of drugs can be a novel tool for dispersing drug nanoparticles in water. Using our method, we were able to produce nanoparticles containing immunosuppressant drug, cyclosporin A, which shows poor solubility toward water, with high levels of the drug using polyvinyl pyrrolidone and sodium dodecyl sulfate as stabilizing agents. The absence of degradation products was confirmed and the loss of pharmaceutical activity with an inhibitory effect on the interleukin-2 production of Jurkat T cells did not occur. Cyclosporin A nanoparticles showed a spherical shape and their particle size was distributed uniformly around 200 nm. Powder X-ray diffraction analysis suggested that cyclosporin A in the nanoparticles was in an amorphous state. In the measurement of solubility rate, the nanoparticle formulation showed a higher rate than that which had not been processed. At present, although this laser irradiation technology has low productivity, it is expected as a new technology for drug nanoparticle manufacturing together with the development of a new laser device.
This paper references
10.1016/J.JCONREL.2004.03.003
Bioavailability and pharmacokinetics of cyclosporine A-loaded pH-sensitive nanoparticles for oral administration.
Xue-qing Wang (2004)
Substrate selectivity and sensitivity to inhibition by FK506 and cyclosporin A of calcineurin heterodimers composed of the alpha or beta catalytic subunit.
B. A. Perrino (2002)
10.1016/J.IJPHARM.2006.02.045
Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals.
R. Mueller (2006)
10.1016/J.JBIOTEC.2004.06.007
Challenges and solutions for the delivery of biotech drugs--a review of drug nanocrystal technology and lipid nanoparticles.
R. H. Muller (2004)
10.1016/S1461-5347(99)00177-7
Lab-scale production unit design for nanosuspensions of sparingly soluble cytotoxic drugs.
Boehm (1999)
10.1248/CPB.51.171
Nanoparticle formation of poorly water-soluble drugs from ternary ground mixtures with PVP and SDS.
K. Itoh (2003)
10.1007/S11051-005-6161-2
Chemical and Structural Properties of Drug–protein Nanocomposites Prepared by Pulsed Laser Deposition from Conjugated Targets
S. Nagare (2006)
10.1016/0378-5173(89)90069-0
The effect of particle size distribution on dissolution rate and oral absorption
R. J. Hintz (1989)
10.1016/S0928-0987(02)00251-8
Nanosizing: a formulation approach for poorly-water-soluble compounds.
E. Merisko-Liversidge (2003)
10.1021/ar800125s
Laser fabrication and spectroscopy of organic nanoparticles.
T. Asahi (2008)
10.1002/JPS.10154
Excipient-drug interactions in parenteral formulations.
M. Akers (2002)
Solubility and mass and nuclear magnetic resonance spectroscopic studies on interaction of cyclosporin A with dimethyl-alpha- and -beta-cyclodextrins in aqueous solution.
K. Miyake (1999)
10.1007/S11051-004-3091-3
Indomethacin nanoparticles directly deposited on the fluidized particulate excipient by pulsed laser deposition
S. Nagare (2004)
10.1248/CPB.41.737
Improved oral absorption of a poorly water-soluble drug, HO-221, by wet-bead milling producing particles in submicron region.
N. Kondo (1993)
10.1021/JS980403L
Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs.
A. T. Serajuddin (1999)
10.1136/bmj.302.6767.4
Cyclosporin: use outside transplantation.
A. Thomson (1991)
10.1016/J.IJPHARM.2004.05.006
pH-sensitive nanoparticles for improving the oral bioavailability of cyclosporine A.
Jundong Dai (2004)
10.1021/JS980284+
Solubility and Mass and Nuclear Magnetic Resonance Spectroscopic Studies on Interaction of Cyclosporin A with Dimethyl‐α‐ and ‐β‐Cyclodextrins in Aqueous Solution
K. Miyake (1999)
10.1111/j.1365-3083.1982.tb00670.x
Inhibition of T‐Cell Activity by Cyclosporin A
L. Andrus (1981)
10.1016/S1056-8719(00)00107-6
Drug-like properties and the causes of poor solubility and poor permeability.
C. Lipinski (2000)
10.1016/S0378-5173(01)00891-2
The mechanisms of drug release from solid dispersions in water-soluble polymers.
D. Craig (2002)
10.2165/00003495-200161130-00006
Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation.
C. Dunn (2001)
Differential effect of cyclosporin A on activation signaling in human T cell lines
B. anger (1986)
10.1016/J.IJPHARM.2004.07.019
The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs.
J. Kipp (2004)
10.1016/S0959-8049(01)00171-X
Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.
H. Gelderblom (2001)
10.1248/BPB.29.1790
Nanocarriers: promising vehicle for bioactive drugs.
M. Rawat (2006)
10.1038/nrd1470
Can the pharmaceutical industry reduce attrition rates?
I. Kola (2004)
10.1172/JCI112464
Differential effect of cyclosporin A on activation signaling in human T cell lines.
B. Manger (1986)
10.1016/S0169-409X(01)00098-9
Amorphous pharmaceutical solids: preparation, characterization and stabilization.
L. Yu (2001)
10.1016/J.JCONREL.2005.02.015
Micelles of methoxy poly(ethylene oxide)-b-poly(epsilon-caprolactone) as vehicles for the solubilization and controlled delivery of cyclosporine A.
H. M. Aliabadi (2005)
10.1016/j.biomaterials.2008.09.016
Multi-morphological biodegradable PLGE nanoparticles and their drug release behavior.
Hanwei Zhang (2009)
10.1016/j.ijpharm.2009.08.042
Particle size analysis of nanocrystals: improved analysis method.
C. Keck (2010)
10.1111/J.1365-2125.1988.TB03318.X
Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985).
R. A. Prentis (1988)
10.1016/S0378-5173(02)00461-1
Positively charged nanoparticles for improving the oral bioavailability of cyclosporin-A.
M. H. El-Shabouri (2002)
10.1016/S0169-409X(01)00105-3
Solid lipid nanoparticles: production, characterization and applications.
W. Mehnert (2001)
10.7326/0003-4819-101-5-667
Cyclosporine: a new immunosuppressive agent for organ transplantation.
D. Cohen (1984)
10.1023/A:1018923912135
Improved Dose Linearity of Cyclosporine Pharmacokinetics from a Microemulsion Formulation
E. A. Mueller (2004)
10.1016/J.IJPHARM.2006.11.030
Preparation of glass solutions of three poorly water soluble drugs by spray drying, melt extrusion and ball milling.
James E Patterson (2007)
10.1046/J.1432-1033.2002.03040.X
Substrate selectivity and sensitivity to inhibition by FK506 and cyclosporin A of calcineurin heterodimers composed of the α or β catalytic subunit
B. A. Perrino (2002)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar